Targeted Therapy For Breast Cancer
作者： Deena M. Atieh , Linda T. Vahdat
DOI: 10.1007/978-1-59745-337-0_14
关键词:
摘要: With the completion of human genome project, confluence information on drivers cell proliferation and emergence technology to define produce therapeutics, molecularly targeted therapies are beginning be integrated into overall treatment patients with cancer. This chapter focuses development, mechanism action, clinical utility these agents in breast Monoclonal antibodies (trastuzumab, bevacizumab, cetiximab), small molecule tyrosine kinase farnesyl transferase inhibitors (gefitinib, erlotinib, lapatinib, tipifarnib), mammalian target rapamycin Raf (temsirolimus, everolimus, sorafenib), other novel (ZD 6474, SU 11248) discussed. In addition, use molecular taxonomy microarray analysis predicting outcomes response therapy reviewed. Key Words: Breast cancer; therapy; trastuzumab; HER-2; microarray; bevacizumab; VEGF; lapatinib; monoclonal antibody; inhibitor.
springer.com
sci-hub.st 参考文章(169)
Sharon Ann Hunt, None, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. ,vol. 46, pp. 1116- 1143 ,(2005) , 10.1016/J.JACC.2005.08.022
V. M. Rivera, J. I. Kreisberg, M. M. Mita, M. Goldston, H. L. Knowles, J. Herson, E. Rowinksy, C. L. Bedrosian, A. Tolcher, Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor Journal of Clinical Oncology. ,vol. 23, pp. 3033- 3033 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.3033
健二郎 青儀, What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及ぼす効果を示した論文:無作為化比較試験のメタアナリシス Mebio oncology. ,vol. 3, pp. 94- 98 ,(2006)
Richard J. Pietras, David Gallardo, P. Nancy Wongvipat, H. Julie Lee, Joseph C. Poen, Dennis J. Slamon, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research. ,vol. 59, pp. 1347- 1355 ,(1999)
Liisa Pertovaara, Arja Kaipainen, Tuija Mustonen, Arto Orpana, Napoleone Ferrara, Olli Saksela, Kari Alitalo, None, Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. Journal of Biological Chemistry. ,vol. 269, pp. 6271- 6274 ,(1994) , 10.1016/S0021-9258(17)37365-9
Maria Theodoulou, Clifford Hudis, Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer. ,vol. 100, pp. 2052- 2063 ,(2004) , 10.1002/CNCR.20207
Stefan Frank, Griseldis Hübner, Georg Breier, Michael T. Longaker, David G. Greenhalgh, Sabine Werner, Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. IMPLICATIONS FOR NORMAL AND IMPAIRED WOUND HEALING Journal of Biological Chemistry. ,vol. 270, pp. 12607- 12613 ,(1995) , 10.1074/JBC.270.21.12607
Carlos L Arteaga, Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer Breast Cancer Research. ,vol. 5, pp. 96- 100 ,(2003) , 10.1186/BCR574
Caroline J. Fuery, Tanya L. Applegate, Walter Wouters, Gerard Sanz, Marc Venet, Ann Devine, Stacy Skrzat, Gerda Smets, David W. End, Charles Bowden, Patrick Angibaud, Alison V. Todd, Herve Poignet, Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro Cancer Research. ,vol. 61, pp. 131- 137 ,(2001)
D. Karunagaran, E. Tzahar, R. R. Beerli, X. Chen, D. Graus-Porta, B. J. Ratzkin, R. Seger, N. E. Hynes, Y. Yarden, ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer The EMBO Journal. ,vol. 15, pp. 254- 264 ,(1996) , 10.1002/J.1460-2075.1996.TB00356.X